Cargando…
Skin Mycobiome of Psoriasis Patients is Retained during Treatment with TNF and IL-17 Inhibitors
Background: Biological treatment relieves refractory skin lesions in patients with psoriasis; however, changes in the fungal microbiome (the mycobiome) on the skin are unclear. Methods: The skin mycobiome of psoriasis patients treated with TNF inhibitors (TNFi, n = 5) and IL-17 inhibitors (IL-17i, n...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312082/ https://www.ncbi.nlm.nih.gov/pubmed/32486022 http://dx.doi.org/10.3390/ijms21113892 |
_version_ | 1783549652606386176 |
---|---|
author | Koike, Yuta Kuwatsuka, Sayaka Nishimoto, Katsutaro Motooka, Daisuke Murota, Hiroyuki |
author_facet | Koike, Yuta Kuwatsuka, Sayaka Nishimoto, Katsutaro Motooka, Daisuke Murota, Hiroyuki |
author_sort | Koike, Yuta |
collection | PubMed |
description | Background: Biological treatment relieves refractory skin lesions in patients with psoriasis; however, changes in the fungal microbiome (the mycobiome) on the skin are unclear. Methods: The skin mycobiome of psoriasis patients treated with TNF inhibitors (TNFi, n = 5) and IL-17 inhibitors (IL-17i, n = 7) was compared with that of patients not receiving systemic therapy (n = 7). Skin swab samples were collected from non-lesional post-auricular areas. Fungal DNA was sequenced by ITS1 metagenomic analysis and taxonomic classification was performed. Results: An average of 37543 reads/sample were analyzed and fungi belonging to 31 genera were detected. The genus Malassezia accounted for >90% of reads in 7/7 samples from the no-therapy group, 4/5 from the TNFi group, and 5/7 from the IL-17i group. Biodiversity was low in those three groups. Few members of the genus trichophyton were detected; the genus Candida was not detected at all. Among the Malassezia species, M. restricta was the major species in 6/7 samples from the no-therapy group, 4/5 from the TNFi group, and 5/7 from the IL-17i group whose the other largest species revealed M. globosa. Conclusions: The mycobiome is retained on post-auricular skin during systemic treatment with TNF and IL-17 inhibitors. |
format | Online Article Text |
id | pubmed-7312082 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73120822020-06-25 Skin Mycobiome of Psoriasis Patients is Retained during Treatment with TNF and IL-17 Inhibitors Koike, Yuta Kuwatsuka, Sayaka Nishimoto, Katsutaro Motooka, Daisuke Murota, Hiroyuki Int J Mol Sci Article Background: Biological treatment relieves refractory skin lesions in patients with psoriasis; however, changes in the fungal microbiome (the mycobiome) on the skin are unclear. Methods: The skin mycobiome of psoriasis patients treated with TNF inhibitors (TNFi, n = 5) and IL-17 inhibitors (IL-17i, n = 7) was compared with that of patients not receiving systemic therapy (n = 7). Skin swab samples were collected from non-lesional post-auricular areas. Fungal DNA was sequenced by ITS1 metagenomic analysis and taxonomic classification was performed. Results: An average of 37543 reads/sample were analyzed and fungi belonging to 31 genera were detected. The genus Malassezia accounted for >90% of reads in 7/7 samples from the no-therapy group, 4/5 from the TNFi group, and 5/7 from the IL-17i group. Biodiversity was low in those three groups. Few members of the genus trichophyton were detected; the genus Candida was not detected at all. Among the Malassezia species, M. restricta was the major species in 6/7 samples from the no-therapy group, 4/5 from the TNFi group, and 5/7 from the IL-17i group whose the other largest species revealed M. globosa. Conclusions: The mycobiome is retained on post-auricular skin during systemic treatment with TNF and IL-17 inhibitors. MDPI 2020-05-29 /pmc/articles/PMC7312082/ /pubmed/32486022 http://dx.doi.org/10.3390/ijms21113892 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Koike, Yuta Kuwatsuka, Sayaka Nishimoto, Katsutaro Motooka, Daisuke Murota, Hiroyuki Skin Mycobiome of Psoriasis Patients is Retained during Treatment with TNF and IL-17 Inhibitors |
title | Skin Mycobiome of Psoriasis Patients is Retained during Treatment with TNF and IL-17 Inhibitors |
title_full | Skin Mycobiome of Psoriasis Patients is Retained during Treatment with TNF and IL-17 Inhibitors |
title_fullStr | Skin Mycobiome of Psoriasis Patients is Retained during Treatment with TNF and IL-17 Inhibitors |
title_full_unstemmed | Skin Mycobiome of Psoriasis Patients is Retained during Treatment with TNF and IL-17 Inhibitors |
title_short | Skin Mycobiome of Psoriasis Patients is Retained during Treatment with TNF and IL-17 Inhibitors |
title_sort | skin mycobiome of psoriasis patients is retained during treatment with tnf and il-17 inhibitors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312082/ https://www.ncbi.nlm.nih.gov/pubmed/32486022 http://dx.doi.org/10.3390/ijms21113892 |
work_keys_str_mv | AT koikeyuta skinmycobiomeofpsoriasispatientsisretainedduringtreatmentwithtnfandil17inhibitors AT kuwatsukasayaka skinmycobiomeofpsoriasispatientsisretainedduringtreatmentwithtnfandil17inhibitors AT nishimotokatsutaro skinmycobiomeofpsoriasispatientsisretainedduringtreatmentwithtnfandil17inhibitors AT motookadaisuke skinmycobiomeofpsoriasispatientsisretainedduringtreatmentwithtnfandil17inhibitors AT murotahiroyuki skinmycobiomeofpsoriasispatientsisretainedduringtreatmentwithtnfandil17inhibitors |